Related Experiment Video
Updated: Jan 26, 2026

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
Published on: June 5, 2019
Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered
Rachael F Grace1, Kristin A Shimano2, Rukhmi Bhat3
1Division of Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts.
Insights
Second-line treatments for immune thrombocytopenia (ITP) in children show varied effects on platelet counts, bleeding, and quality of life. Romiplostim and rituximab effectively reduced bleeding, while eltrombopag improved quality of life.
Area of Science:
- Pediatric Hematology
- Autoimmune Diseases
- Clinical Outcomes Research
Background:
- Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder in children.
- Second-line treatments are necessary when observation is insufficient or to improve quality of life (HRQoL).
- Comparative data on second-line treatment outcomes for pediatric ITP is limited.
Purpose of the Study:
- To compare outcomes of second-line treatments for pediatric ITP.
- To evaluate effects on platelet count, bleeding symptoms, and HRQoL.
Main Methods:
- ICON1: A prospective, multi-center, observational study.
- 120 children initiating second-line ITP treatment.
- Outcomes assessed using platelet counts, bleeding assessments, and the Kids ITP Tool (KIT) for HRQoL.
Main Results:
- All treatments increased platelet counts; romiplostim showed the most significant effect at 6 months.
- Romilostim and rituximab significantly reduced both skin and non-skin bleeding symptoms within 1 month.
- HRQoL improved with all treatments; eltrombopag met the minimal important difference (MID) for KIT scores at 1 month.
Conclusions:
- Second-line treatments for pediatric ITP vary in their efficacy and timing of effect on platelet count, bleeding, and HRQoL.
- Romilostim and rituximab demonstrated notable reductions in bleeding, while eltrombopag showed significant HRQoL improvements.
- Findings are hypothesis-generating for optimizing individual treatment selection in pediatric ITP, pending further randomized trials.
Abstract:
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with isolated thrombocytopenia and hemorrhagic risk. While many children with ITP can be safely observed, treatments are often needed for various reasons, including to decrease bleeding, or to improve health related quality of life (HRQoL). There are a number of available second-line treatments, including rituximab, thrombopoietin-receptor agonists, oral immunosuppressive agents, and splenectomy, but data comparing treatment outcomes are lacking. ICON1 is a prospective, multi-center, observational study of 120 children starting second-line treatments for ITP designed to compare treatment outcomes including platelet count, bleeding, and HRQoL utilizing the Kids ITP Tool (KIT). While all treatments resulted in increased platelet counts, romiplostim had the most pronounced effect at 6 months (P = .04). Only patients on romiplostim and rituximab had a significant reduction in both skin-related (84% to 48%, P = .01 and 81% to 43%, P = .004) and non-skin-related bleeding symptoms (58% to 14%, P = .0001 and 54% to 17%, P = .0006) after 1 month of treatment. HRQoL significantly improved on all treatments. However, only patients treated with eltrombopag had a median improvement in KIT scores at 1 month that met the minimal important difference (MID). Bleeding, platelet count, and HRQoL improved in each treatment group, but the extent and timing of the effect varied among treatments. These results are hypothesis generating and help to improve our understanding of the effect of each treatment on specific patient outcomes. Combined with future randomized trials, these findings will help clinicians select the optimal second-line treatment for an individual child with ITP.
More Related Videos
08:44Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
Published on: September 7, 2022
14:38Preparation, Procedures and Evaluation of Platelet-Rich Plasma Injection in the Treatment of Knee Osteoarthritis
Published on: January 4, 2019
Related Concept Videos
Patient-centered Care
Lattice Centering and Coordination Number
Types of Unit Cells
Imagine taking a large number of identical...
Center of Gravity
Center of Gravity
To determine its location, the principle of moments can be utilized by dividing the object into...
Predicting Reaction Outcomes
Center of Mass
The knowledge of the center of mass can also help us to describe and predict the motion of objects. For example, when a ball is thrown...